- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022–2027 · career development · K08
A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer
Miryam Yusufov · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Engineering dendritic cells to target islet antigen to pro-tolerogenic subsets for prevention and treatment of Type 1 Diabetes
Judith Agudo Cantero · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PCRP
Prostate Cancer Clinical Trials Consortium: Dana-Farber
Mary-Ellen Taplin · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · program · P50
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Genomic Diversity of Prostate Cancer Across the African Diaspora
Timothy R Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · fellowship · CIHR Fellowship
Dissequer la pertinence fonctionnelle de l'heterogeneite d'HER2 dans le cancer du sein pour de nouvelles strategies therapeutiques
Marie-Anne Goyette · Dana-Farber Cancer Institute · funded by Canadian Institutes of Health Research
2022–2027 · research · R01
Cyclin C-CDK8/19 kinases in development and in cancer
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation
Erin M Parry · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · career development · K00
Targeting Oncogenic Drivers in Cancer
Matthew W Boudreau · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cell lineage as an indicator of immune response in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2028 · career development · K00
SIRT1 Regulates RNA Stability to Promote Breast Cancer
Fangyu Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · KCRP
Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear Cell Renal Cell Carcinoma
Qinqin Jiang · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2026 · grant · PRCRP
Defining the Regulation of GD2 Expression to Enhance Immunotherapy for Neuroblastoma
Robbie Majzner · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R01
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
Geoffrey I Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
Geoffrey I Shapiro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PCRP
Epigenetic Regulators of Lineage Plasticity in Prostate Cancer
Varadha Balaji Venkadakrishnan · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2026 · research · R01
Systematic identification of minor histocompatibility antigens to address GVHD
Vincent Trien-Vinh Ho · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2028 · research · R01
Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial Stress
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Systematic identification of minor histocompatibility antigens to address GVHD
Vincent Trien-Vinh Ho · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · KCRP
Developing a Novel Therapeutic Target in Xp11.2 Translocation Renal Cell Carcinoma
Jiao Li · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2026 · grant · PCRP
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients with Androgen Deprivation Therapy: The POWER Trial
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · research · R01
Promoting Resilience in Early Survivorship among Adolescents and Young Adults with Cancer
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer
Miryam Yusufov · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2023 · research · R21
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Regulation and targeting of tumor cell states and plasticity in pancreatic cancer
Srivatsan Raghavan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Defining the landscape and mechanisms of protein redox regulation during aging
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · grant · PCRP
Interrogating Metastatic Prostate Cancer Biological and Clinical Trajectories Through Integrative Data Science
Kenneth Kehl · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2023 · research · R21
Targeting MUC1-C for the Treatment of Small Cell Lung Cancer Progression
Donald W. Kufe · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Matthew S Davids · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Matthew S Davids · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · research · R00
Mechanistic characterization of the anti-inflammatory function of thermogenic fat for the treatment of metabolic disorders
Evanna Louisa Mills · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2024 · career development · K99
Defining the landscape and mechanisms of redox regulation of metabolism during aging
Haopeng Xiao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · career development · K00
Targeting Oncogenic Drivers in Cancer
Matthew W Boudreau · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Novel targeted therapies for chronic myelomonocytic leukemia
Roger Vincent Belizaire · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · grant · PRCRP
Noninvasive Diagnosis of Immune Checkpoint Inhibitor-Associated Myocarditis
Mohammad Rashidian · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2022–2027 · career development · K08
Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer
William A Freed-Pastor · Dana-Farber Cancer Institute · funded by National Institutes of Health
